logo

Diseases and Drugs

Share

fda-nov26.jpg With already 51 new molecular entities, or NMEs, getting greenlighted by the FDA so far this year, and still 1 more month to go, 2018 could be a banner year. This outpaces the 53 new drugs approved in 1996 - the highest ever.

fda-oct29.jpg As another month comes to a close, it's time to take a look back at some of the pharma news stories of October, and look ahead at what's coming next over the horizon on the regulatory front.

octobercalendar-sept28.jpg As we head into another month of new drug approvals, it's time to take a look at some of the FDA-related news that grabbed headlines in September. Seeking to curb the sharp rise in the number of teens using e-cigarettes, the FDA, has expanded its Youth Tobacco Prevention Plan, which was first introduced last April.

calendar-sep-083018.jpg August proved to be a very busy month on the regulatory front, in terms of Novel Drug approvals, the ongoing efforts to restrict opioid abuse, and new efforts to encourage further advances in the rapidly evolving field of gene therapy. Now, let's take a look at the biotech stocks awaiting FDA decision in September.

fda-aug17.jpg In the month of July, 9 drugs were approved by the FDA, including novel drugs and biosimilars.

pharma-august-072518.jpg As another month comes to a close, it's time to take a look back at some of the biggest news stories of July on the pharma sector, and look ahead at what's coming next over the horizon on the regulatory front.

usfood-july16.jpg The process of drug development is challenging. Some drugs pass the FDA muster easily, while some face a host of hurdles before getting the official stamp of approval. As of this writing, 21 novel drugs have been approved by the FDA so far this year. Novel drugs are new molecular entities (NMEs) having...

alzheimers-july3.jpg The development of Alzheimer's drugs has been marred by a high failure rate. Despite the high failure rate, the pharma companies have not shied away from making investments in Alzheimer's research. Let's take a look at the companies whose Alzheimer's drugs are in phase III development.

july2018-june29.jpg We are halfway through the year, and it's time to take a look back at some of the regulatory news that made headlines in June and look ahead to what lies in store for the biotech stocks at the FDA altar.

fda-june15.jpg The bench to bedside journey of drugs is no easy task. Some drug candidates fail to complete the journey while many make it to the finish line only after undergoing numerous obstacles.

topstory-june-052918.jpg Time is flying, and we are already five months into the year. Thirteen novel drugs have been approved by the FDA so far in 2018 - with 4 being greenlighted in the month of May. Now, let's take a look at the biotech stocks that await FDA word in June 2018.

calendar-042718.jpg Another busy month at the FDA is coming to an end, and it's that time again to take a look at the upcoming action dates of approval, and panel review dates in May.

humira-042418.jpg CLICK HERE to see America's 10 Best-Selling Drugs Despite high drug costs, most of the top-selling drugs saw sales gains in 2017 compared to the prior year. A large number of the best-selling drugs are primarily for the treatment and management of cancer, diabetes, inflammatory disorders, and HIV...

fda-approved-march2018-040218.jpg Only two novel drugs were approved by the FDA in March compared to seven drug approvals in the same month last year. Novel drugs are new molecular entities (NMEs) having chemical structures that have never been approved before. Trogarzo received green signal from the FDA on March 6, 2018, while Ilumya was approved by the FDA on March 20, 2018.

sickle-cell-disease-040618.jpg Sickle cell disease, or SCD in short, refers to a group of inherited red blood cell disorders. In these patients, the hemoglobin protein present inside the red blood cells is abnormal, causing the RBCs to become rigid, sticky and "C" or sickle, shaped. Let us take a look at some of the companies developing treatments for sickle cell disease.

Follow RTT